Not provided
Not provided
Not provided
Not provided
Not provided
Major side-effects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The uremic syndrome is mainly related to the retention of a host of compounds, due to altered glomerular filtration and other factors of renal dysfunction, e.g. tubular secretion. Uremic retention solutes are arbitrarily subdivided in three different categories according to their physicochemical characteristics and their subsequent behaviour during dialysis: (i) the small, water-soluble, non-protein bound compounds, (ii) the larger middle molecules, mainly peptides and (iii) the small protein-bound compounds (1).
Although direct proof is lacking, several lines of evidence indicate that albumin is the most important carrier protein. Removal of protein bound uremic retention solutes is limited.
The Prometheus® system fractionates blood into plasma and cellular components, using an albumin-permeable polysulfon filter (AlbuFlow®) with a specially designed sieving coefficient curve (1.0 for 2-microglobulin, >0.6 for albumin, <0.3 for IgG, <0.1 for fibrinogen and <0.01 for IgM). Due to the high sieving coefficient of the filter for large molecules (i.e. cut-off at about 250 kD) molecules up to the size of albumin (69 kD) easily pass from blood into the secondary circuit which is filled with isotonic sodium chloride solution, whereas larger molecules like fibrinogen (340 kD) cannot pass through the filter. In the secondary circuit the filtered plasma with the albumin-bound toxins flows through one or two adsorbers in a row with maximized adsorption capacity for putative liver toxins that are directly adsorbed ('fractionated plasma separation and adsorption' or FPSA). The purified plasma is then returned to the blood side of the albumin filter. In order to eliminate water-soluble toxins, blood thereafter undergoes hemodialysis using a conventional high-flux dialyser.
We hypothesise that removal of protein bound uremic retention solutes can be improved by FPSA as compared to standard hemodialysis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fractionated Plasma Separation and Adsorption (FPSA) | Device |
| Measure | Description | Time Frame |
|---|---|---|
| Uremic retention solute reduction rate | ||
| Biocompatibility |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pieter Evenepoel, MD | UZ Leuven | Study Director |
| Kathleen Claes, MD | UZ Leuven | Principal Investigator |
| Björn Meijers, MD | UZ Leuven | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universitaire Ziekenhuizen Leuven | Leuven | Vlaams-Brabant | 3000 | Belgium |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Mar 4, 2009 | |
| Reset | Apr 3, 2009 | |
| Release | Apr 6, 2009 | |
| Reset | May 28, 2009 | |
| Release | Sep 14, 2011 | |
| Reset | Oct 21, 2011 | |
| Release | Jan 6, 2012 | |
| Reset | Feb 8, 2012 | |
| Release | Aug 1, 2012 | |
| Reset | Aug 30, 2012 | |
| Release | Dec 5, 2012 | |
| Reset | Jan 9, 2013 | |
| Release | Jan 27, 2023 | |
| Reset | Nov 8, 2023 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Mar 4, 2009 | Apr 3, 2009 | |||
| Apr 6, 2009 |
| ID | Term |
|---|---|
| D051436 | Renal Insufficiency, Chronic |
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| May 28, 2009 |
| Sep 14, 2011 | Oct 21, 2011 |
| Jan 6, 2012 | Feb 8, 2012 |
| Aug 1, 2012 | Aug 30, 2012 |
| Dec 5, 2012 | Jan 9, 2013 |
| Jan 27, 2023 | Nov 8, 2023 |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |